|
|
(7 intermediate revisions by 2 users not shown) |
redirect | redirect |
| | Q3698691 |
label / fr | label / fr |
| 12012 - MIMEDI
|
label / en | label / en |
| 12012 – MIMEDI
|
label / de | label / de |
| 12012 – MIMEDI
|
description / en | description / en |
| Project Q190706 in France
|
description / fr | description / fr |
| Projet Q190706 en France
|
Property / French Kohesio ID | |
| 10341
| |
Property / French Kohesio ID: 10341 / rank | |
| Normal rank
| |
Property / instance of | |
| | |
Property / instance of: Kohesio project / rank | |
| Normal rank
| |
Property / country | |
| | |
Property / country: France / rank | |
| Normal rank
| |
Property / EU contribution | |
| 10,211,026.83 EuroAmount | 10,211,026.83 Euro |
---|
Unit | Euro |
---|
| |
Property / EU contribution: 10,211,026.83 Euro / rank | |
| Normal rank
| |
Property / budget | |
| 13,614,711.32 EuroAmount | 13,614,711.32 Euro |
---|
Unit | Euro |
---|
| |
Property / budget: 13,614,711.32 Euro / rank | |
| Normal rank
| |
Property / postal code | |
| 25030
| |
Property / postal code: 25030 / rank | |
| Normal rank
| |
Property / start time | |
| 1 December 2017Timestamp | +2017-12-01T00:00:00Z |
---|
Timezone | +00:00 |
---|
Calendar | Gregorian |
---|
Precision | 1 day |
---|
Before | 0 |
---|
After | 0 |
---|
| |
Property / start time: 1 December 2017 / rank | |
| Normal rank
| |
Property / end time | |
| 30 November 2021Timestamp | +2021-11-30T00:00:00Z |
---|
Timezone | +00:00 |
---|
Calendar | Gregorian |
---|
Precision | 1 day |
---|
Before | 0 |
---|
After | 0 |
---|
| |
Property / end time: 30 November 2021 / rank | |
| Normal rank
| |
Property / beneficiary name (string) | |
| Université de Franche-Comté
| |
Property / beneficiary name (string): Université de Franche-Comté / rank | |
| Normal rank
| |
Property / summary | |
| Les médicaments innovants (MédI) ont récemment émergé afin de proposer de nouvelles solutions de traitement pour les patients en impasse thérapeutique. Ces MédI sont basés sur l’utilisation de cellules « médicaments ». Or, la fabrication de ces médicaments nécessite de mettre en oeuvre des technologies complexes et donc coûteuses. MiMédi a pour ambition de rationaliser leur fabrication en apportant de nouvelles solutions techniques et en optimisant l’ensemble des étapes nécessaires à leur production. Pour se faire, MiMédi associe des laboratoires de recherche et des industriels francs-comtois aussi bien issus des sciences de l’ingénieur que de l’ingénierie cellulaire. (French)
| |
Property / summary: Les médicaments innovants (MédI) ont récemment émergé afin de proposer de nouvelles solutions de traitement pour les patients en impasse thérapeutique. Ces MédI sont basés sur l’utilisation de cellules « médicaments ». Or, la fabrication de ces médicaments nécessite de mettre en oeuvre des technologies complexes et donc coûteuses. MiMédi a pour ambition de rationaliser leur fabrication en apportant de nouvelles solutions techniques et en optimisant l’ensemble des étapes nécessaires à leur production. Pour se faire, MiMédi associe des laboratoires de recherche et des industriels francs-comtois aussi bien issus des sciences de l’ingénieur que de l’ingénierie cellulaire. (French) / rank | |
| Normal rank
| |
Property / summary | |
| Innovative medicines (medium) have recently emerged to propose new treatment solutions for patients with therapeutic deadlocks. These media are based on the use of “drug” cells. However, the manufacture of these drugs requires the implementation of complex and therefore costly technologies. MiMédi aims to streamline their manufacturing by providing new technical solutions and optimising all the steps necessary for their production. To do so, MiMédi associates research laboratories and Franc-comtois industrialists from both engineering and cellular engineering. (English)
| |
Property / summary: Innovative medicines (medium) have recently emerged to propose new treatment solutions for patients with therapeutic deadlocks. These media are based on the use of “drug” cells. However, the manufacture of these drugs requires the implementation of complex and therefore costly technologies. MiMédi aims to streamline their manufacturing by providing new technical solutions and optimising all the steps necessary for their production. To do so, MiMédi associates research laboratories and Franc-comtois industrialists from both engineering and cellular engineering. (English) / rank | |
| Normal rank
| |
Property / summary: Innovative medicines (medium) have recently emerged to propose new treatment solutions for patients with therapeutic deadlocks. These media are based on the use of “drug” cells. However, the manufacture of these drugs requires the implementation of complex and therefore costly technologies. MiMédi aims to streamline their manufacturing by providing new technical solutions and optimising all the steps necessary for their production. To do so, MiMédi associates research laboratories and Franc-comtois industrialists from both engineering and cellular engineering. (English) / qualifier | |
| point in time: 13 October 2020Timestamp | +2020-10-13T00:00:00Z |
---|
Timezone | +00:00 |
---|
Calendar | Gregorian |
---|
Precision | 1 day |
---|
Before | 0 |
---|
After | 0 |
---|
| |
Property / intervention field | |
| | |
Property / intervention field: Technology transfer and university-enterprise cooperation primarily benefiting SMEs / rank | |
| Normal rank
| |
Property / coordinate location | |
| 47°14'23.03"N, 6°0'44.14"ELatitude | 47.239733666667 |
---|
Longitude | 6.0122559333333 |
---|
Precision | 1.0E-5 |
---|
Globe | http://www.wikidata.org/entity/Q2 |
---|
| |
Property / coordinate location: 47°14'23.03"N, 6°0'44.14"E / rank | |
| Normal rank
| |
Property / financed by | |
| | |
Property / financed by: European Union / rank | |
| Normal rank
| |
Property / programme | |
| | |
Property / programme: Franche-Comté et Jura - ERDF/ESF / rank | |
| Normal rank
| |
Property / co-financing rate | |
| | |
Property / co-financing rate: 75.0 percent / rank | |
| Normal rank
| |
Property / beneficiary | |
| Q2537920 (Deleted Item)
| |
Property / beneficiary: Q2537920 (Deleted Item) / rank | |
| Normal rank
| |
Property / ID used by InfoRegio | |
| 4607
| |
Property / ID used by InfoRegio: 4607 / rank | |
| Normal rank
| |
Property / info Regio url | |
| | |
Property / info Regio url: https://ec.europa.eu/regional_policy/en/projects/europe/mimedi-optimiser-la-fabrication-de-medicaments-innovants-en-evitant-le-recours-aux-salles-blanches / rank | |
| Normal rank
| |
Property / image url | |
| | |
Property / image url: https://ec.europa.eu/regional_policy/rest/projects/upload/4607.jpg / rank | |
| Normal rank
| |
Property / image url: https://ec.europa.eu/regional_policy/rest/projects/upload/4607.jpg / qualifier | |
| summary: Device for biological element sorting by acoustophoresis. (English) | |
Property / image url: https://ec.europa.eu/regional_policy/rest/projects/upload/4607.jpg / qualifier | |
| copyright: Quarroz – FEMTO, Univ-Franche-Comte 2018 | |
Property / fund | |
| | |
Property / fund: European Regional Development Fund / rank | |
| Normal rank
| |
Property / contained in NUTS | |
| | |
Property / contained in NUTS: Doubs / rank | |
| Normal rank
| |